Bristol-Myers Squibb BMY Krazati — Total Revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bristol-Myers Squibb's krazati — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bristol-Myers Squibb's krazati — total revenues?
- Bristol-Myers Squibb (BMY) reported krazati — total revenues of $55M in Q2 2026.
- How has Bristol-Myers Squibb's krazati — total revenues changed year-over-year?
- Bristol-Myers Squibb's krazati — total revenues increased by 14.6% year-over-year, from $48M to $55M.
- What does krazati — total revenues mean?
- This metric represents the total net sales generated from the commercialization of Krazati, a targeted therapy for specific oncological indications. It reflects the market adoption, pricing power, and clinical demand for this specific therapeutic asset within the company's oncology portfolio. Tracking this revenue stream is critical for assessing the commercial success of the company's precision medicine pipeline and its ability to capture market share in competitive cancer treatment segments.